Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $22.30 USD
Change Today -7.00 / -23.89%
Volume 1.7M
FMI On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

foundation medicine inc (FMI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - $54.28
52 Week Low
10/1/14 - $18.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

foundation medicine inc (FMI) Related Businessweek News

View More BusinessWeek News

foundation medicine inc (FMI) Details

Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The company provides clinical products, such as FoundationOne for solid tumors; and FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers. It also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, foster relationships throughout the oncology community, and develop new clinical and technology products. In addition, the company has a strategic collaboration agreement with WuXi PharmaTech Inc. to provide genomic profiles to biopharmaceutical companies conducting clinical trials; and F. Hoffmann-La Roche Ltd. to develop and commercialize molecular information and genomic analysis products for the treatment of cancer patients. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts.

293 Employees
Last Reported Date: 03/13/15
Founded in 2009

foundation medicine inc (FMI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $416.0K
President and Chief Operating Officer
Total Annual Compensation: $357.8K
Chief Medical Officer
Total Annual Compensation: $357.9K
Chief Commercial Officer
Total Annual Compensation: $50.6K
Compensation as of Fiscal Year 2014.

foundation medicine inc (FMI) Key Developments

Foundation Medicine, Inc. to Report Q2, 2015 Results on Jul 29, 2015

Foundation Medicine, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Jul 29, 2015

Foundation Medicine, Inc., Q2 2015 Earnings Call, Jul 29, 2015

Foundation Medicine, Inc., Q2 2015 Earnings Call, Jul 29, 2015

IMS Health and Foundation Medicine Announce Collaboration to Optimize Targeting of Precision Therapies in Oncology

IMS Health and Foundation Medicine, Inc. announced a collaboration to advance the understanding and effectiveness of precision medicines for treating cancer. Commercial, medical and outcomes research teams in biopharma and life sciences companies will now be able to leverage an offering that combines IMS Health’s powerful Real-World Evidence platform providing clinical and cost-of-care insights with Foundation Medicine’s dynamic knowledgebase of comprehensive cancer genomic profiles, all at the patient-anonymous level. Through the collaboration, IMS Health’s clients will gain unprecedented insights to rapidly assess health outcomes and effectiveness, and to improve cancer care by better connecting patients to the right targeted therapies at the right time. These enhanced oncologic insights will be powered by Evidence 360 and FoundationCORE. Evidence 360 is IMS Health’s scalable and secure RWE platform that helps clients extract, analyze and visualize real-world data to better understand and measure healthcare outcomes. It brings together IMS Health’s vast library of patient-anonymous data with other patient-anonymous sources of health information to help life sciences companies interpret real-world outcomes and better target their commercial efforts. FoundationCORE is a molecular information knowledgebase containing comprehensive cancer genomic information and insights from more than 43,000 clinical cases profiled by Foundation Medicine. FoundationCORE evolves in real-time, informed by every new cancer patient tested with the company’s commercial assays, FoundationOne and FoundationOne Heme.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMI:US $22.30 USD -7.00

FMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $19.74 USD -0.85
Luminex Corp $17.05 USD -0.14
NanoString Technologies Inc $15.18 USD +0.18
NeoGenomics Inc $6.05 USD +0.08
Veracyte Inc $11.13 USD -0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation FMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOUNDATION MEDICINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at